Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial

PURPOSE: TAS-102 is a combination of the thymidine-based nucleoside analog trifluridine and the thymidine phosphorylase inhibitor tipiracil. Efficacy and safety of TAS-102 in patients with metastatic colorectal cancer (mCRC) refractory or intolerant to standard therapies were evaluated in the phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Longo-Muñoz, F., Argiles, G., Tabernero, J., Cervantes, A., Gravalos, C., Pericay, C., Gil-Calle, S., Mizuguchi, H., Carrato-Mena, A., Limón, M. L., Garcia-Carbonero , R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239803/
https://www.ncbi.nlm.nih.gov/pubmed/27443414
http://dx.doi.org/10.1007/s12094-016-1528-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5239803/
https://www.ncbi.nlm.nih.gov/pubmed/27443414
http://dx.doi.org/10.1007/s12094-016-1528-7

Ejemplares similares